Puromycin is an antibiotic that prevents bacterial protein translation. It is utilized as a selective agent in laboratory cell cultures. Puromycin is toxic to both prokaryotic and eukaryotic cells, resulting in significant cell death at appropriate doses.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Succinylcholine | The therapeutic efficacy of Succinylcholine can be increased when used in combination with Puromycin. |
| Metocurine iodide | The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Puromycin. |
| Gallamine triethiodide | The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Puromycin. |
| Cisatracurium | Puromycin may increase the neuromuscular blocking activities of Cisatracurium. |
| Rocuronium | The therapeutic efficacy of Rocuronium can be increased when used in combination with Puromycin. |
| Atracurium besylate | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Puromycin. |
| Doxacurium | The therapeutic efficacy of Doxacurium can be increased when used in combination with Puromycin. |
| Mivacurium | The therapeutic efficacy of Mivacurium can be increased when used in combination with Puromycin. |
| Decamethonium | The therapeutic efficacy of Decamethonium can be increased when used in combination with Puromycin. |
| Metocurine | The therapeutic efficacy of Metocurine can be increased when used in combination with Puromycin. |
| Pancuronium | The therapeutic efficacy of Pancuronium can be increased when used in combination with Puromycin. |
| Pipecuronium | The therapeutic efficacy of Pipecuronium can be increased when used in combination with Puromycin. |
| Vecuronium | The therapeutic efficacy of Vecuronium can be increased when used in combination with Puromycin. |
| Rapacuronium | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Puromycin. |
| Pyrantel | The therapeutic efficacy of Pyrantel can be increased when used in combination with Puromycin. |
| Neosaxitoxin | The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Puromycin. |
| Atracurium | The therapeutic efficacy of Atracurium can be increased when used in combination with Puromycin. |
| Gallamine | The therapeutic efficacy of Gallamine can be increased when used in combination with Puromycin. |
| Alcuronium | The therapeutic efficacy of Alcuronium can be increased when used in combination with Puromycin. |
| Tubocurarine | The therapeutic efficacy of Tubocurarine can be increased when used in combination with Puromycin. |
| Carboplatin | The risk or severity of ototoxicity and nephrotoxicity can be increased when Puromycin is combined with Carboplatin. |
| Foscarnet | The risk or severity of nephrotoxicity can be increased when Puromycin is combined with Foscarnet. |
| Mannitol | The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Puromycin. |
| Tenofovir disoproxil | Puromycin may increase the nephrotoxic activities of Tenofovir disoproxil. |
| Tenofovir alafenamide | Puromycin may increase the nephrotoxic activities of Tenofovir alafenamide. |
| Tenofovir | Puromycin may increase the nephrotoxic activities of Tenofovir. |
| Picosulfuric acid | The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Puromycin. |
| Zoledronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Puromycin is combined with Zoledronic acid. |
| Alendronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Puromycin is combined with Alendronic acid. |
| Ibandronate | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Puromycin is combined with Ibandronate. |
| Clodronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Puromycin is combined with Clodronic acid. |
| Risedronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Puromycin is combined with Risedronic acid. |
| Etidronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Puromycin is combined with Etidronic acid. |
| Incadronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Puromycin is combined with Incadronic acid. |
| Pamidronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Puromycin is combined with Pamidronic acid. |
| Tiludronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Puromycin is combined with Tiludronic acid. |
| Cyclosporine | The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Puromycin. |
| Icosapent | The risk or severity of nephrotoxicity can be increased when Icosapent is combined with Puromycin. |
| Cefotiam | The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Puromycin. |
| Mesalazine | The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Puromycin. |
| Cefmenoxime | The risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Puromycin. |
| Cefmetazole | The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Puromycin. |
| Indomethacin | The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Puromycin. |
| Cidofovir | The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Puromycin. |
| Triamterene | The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Puromycin. |
| Cefpiramide | The risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Puromycin. |
| Ceftazidime | The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Puromycin. |
| Loracarbef | The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Puromycin. |
| Framycetin | The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Puromycin. |
| Cefalotin | The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Puromycin. |
| Nabumetone | The risk or severity of nephrotoxicity can be increased when Nabumetone is combined with Puromycin. |
| Ketorolac | The risk or severity of nephrotoxicity can be increased when Ketorolac is combined with Puromycin. |
| Tenoxicam | The risk or severity of nephrotoxicity can be increased when Tenoxicam is combined with Puromycin. |
| Celecoxib | The risk or severity of nephrotoxicity can be increased when Celecoxib is combined with Puromycin. |
| Cefotaxime | The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Puromycin. |
| Tolmetin | The risk or severity of nephrotoxicity can be increased when Tolmetin is combined with Puromycin. |
| Rofecoxib | The risk or severity of nephrotoxicity can be increased when Rofecoxib is combined with Puromycin. |
| Piroxicam | The risk or severity of nephrotoxicity can be increased when Piroxicam is combined with Puromycin. |
| Methotrexate | The risk or severity of nephrotoxicity can be increased when Methotrexate is combined with Puromycin. |
| Cephalexin | The risk or severity of nephrotoxicity can be increased when Cephalexin is combined with Puromycin. |
| Fenoprofen | The risk or severity of nephrotoxicity can be increased when Fenoprofen is combined with Puromycin. |
| Valaciclovir | The risk or severity of nephrotoxicity can be increased when Valaciclovir is combined with Puromycin. |
| Valdecoxib | The risk or severity of nephrotoxicity can be increased when Valdecoxib is combined with Puromycin. |
| Diclofenac | The risk or severity of nephrotoxicity can be increased when Diclofenac is combined with Puromycin. |
| Sulindac | The risk or severity of nephrotoxicity can be increased when Sulindac is combined with Puromycin. |
| Bacitracin | The risk or severity of nephrotoxicity can be increased when Bacitracin is combined with Puromycin. |
| Amphotericin B | The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Puromycin. |
| Cephaloglycin | The risk or severity of nephrotoxicity can be increased when Cephaloglycin is combined with Puromycin. |
| Flurbiprofen | The risk or severity of nephrotoxicity can be increased when Flurbiprofen is combined with Puromycin. |
| Adefovir dipivoxil | The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Puromycin. |
| Pentamidine | The risk or severity of nephrotoxicity can be increased when Pentamidine is combined with Puromycin. |
| Etodolac | The risk or severity of nephrotoxicity can be increased when Etodolac is combined with Puromycin. |
| Mefenamic acid | The risk or severity of nephrotoxicity can be increased when Mefenamic acid is combined with Puromycin. |
| Acyclovir | The risk or severity of nephrotoxicity can be increased when Acyclovir is combined with Puromycin. |
| Naproxen | The risk or severity of nephrotoxicity can be increased when Naproxen is combined with Puromycin. |
| Sulfasalazine | The risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Puromycin. |
| Phenylbutazone | The risk or severity of nephrotoxicity can be increased when Phenylbutazone is combined with Puromycin. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Puromycin is combined with Meloxicam. |
| Carprofen | The risk or severity of nephrotoxicity can be increased when Carprofen is combined with Puromycin. |
| Cefaclor | The risk or severity of nephrotoxicity can be increased when Cefaclor is combined with Puromycin. |
| Diflunisal | The risk or severity of nephrotoxicity can be increased when Diflunisal is combined with Puromycin. |
| Tacrolimus | The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Puromycin. |
| Ceforanide | The risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Puromycin. |
| Salicylic acid | The risk or severity of nephrotoxicity can be increased when Salicylic acid is combined with Puromycin. |
| Meclofenamic acid | The risk or severity of nephrotoxicity can be increased when Meclofenamic acid is combined with Puromycin. |
| Acetylsalicylic acid | The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Puromycin. |
| Oxaprozin | The risk or severity of nephrotoxicity can be increased when Oxaprozin is combined with Puromycin. |
| Hydrochlorothiazide | The risk or severity of nephrotoxicity can be increased when Hydrochlorothiazide is combined with Puromycin. |
| Ketoprofen | The risk or severity of nephrotoxicity can be increased when Ketoprofen is combined with Puromycin. |
| Balsalazide | The risk or severity of nephrotoxicity can be increased when Balsalazide is combined with Puromycin. |
| Ibuprofen | The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Puromycin. |
| Cefditoren | The risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Puromycin. |
| Atazanavir | The risk or severity of nephrotoxicity can be increased when Atazanavir is combined with Puromycin. |
| Colistimethate | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Puromycin. |
| Cefuroxime | The risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Puromycin. |
| Cefapirin | The risk or severity of nephrotoxicity can be increased when Cefapirin is combined with Puromycin. |
| Cefadroxil | The risk or severity of nephrotoxicity can be increased when Cefadroxil is combined with Puromycin. |
| Cefprozil | The risk or severity of nephrotoxicity can be increased when Cefprozil is combined with Puromycin. |
| Ceftriaxone | The risk or severity of nephrotoxicity can be increased when Ceftriaxone is combined with Puromycin. |
| Olsalazine | The risk or severity of nephrotoxicity can be increased when Puromycin is combined with Olsalazine. |